Evidence map›Paper›PMID 25618405›Full record

ArticleThe international journal of neuropsychopharmacology2015

Preclinical Assessment of Lisdexamfetamine as an Agonist Medication Candidate for Cocaine Addiction: Effects in Rhesus Monkeys Trained to Discriminate Cocaine or to Self-Administer Cocaine in a Cocaine Versus Food Choice Procedure.

Matthew L Banks, Blake A Hutsell, Bruce E Blough, Justin L Poklis, S Stevens Negus

Open access · goldAbstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in The international journal of neuropsychopharmacology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
3.9field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 44 citations in OpenAlex.

  1. Open-label pilot study of lisdexamfetamine for cocaine use disorder.The American journal of drug and alcohol abuse · 2021
    Trial
  2. Trial
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Effects of Acute and Chronic Treatments with Dopamine DThe Journal of pharmacology and experimental therapeutics · 2017
    Article
  11. Article
  12. Review
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Matthew L BanksDepartment of Pharmacology and Toxicology, Virginia Commonwealth University, Richmond, VA (Drs Banks, Hutsell, Negus, and Mr Poklis); Institute for Drug and Alcohol Studies, Virginia Commonwealth University, Richmond, VA (Drs Banks and Negus); Center for Drug Discovery, Research Triangle Institute, Research Triangle Park, NC (Dr Blough) mbanks7@vcu.edu.
Blake A HutsellDepartment of Pharmacology and Toxicology, Virginia Commonwealth University, Richmond, VA (Drs Banks, Hutsell, Negus, and Mr Poklis); Institute for Drug and Alcohol Studies, Virginia Commonwealth University, Richmond, VA (Drs Banks and Negus); Center for Drug Discovery, Research Triangle Institute, Research Triangle Park, NC (Dr Blough).
Bruce E BloughDepartment of Pharmacology and Toxicology, Virginia Commonwealth University, Richmond, VA (Drs Banks, Hutsell, Negus, and Mr Poklis); Institute for Drug and Alcohol Studies, Virginia Commonwealth University, Richmond, VA (Drs Banks and Negus); Center for Drug Discovery, Research Triangle Institute, Research Triangle Park, NC (Dr Blough).
Justin L PoklisDepartment of Pharmacology and Toxicology, Virginia Commonwealth University, Richmond, VA (Drs Banks, Hutsell, Negus, and Mr Poklis); Institute for Drug and Alcohol Studies, Virginia Commonwealth University, Richmond, VA (Drs Banks and Negus); Center for Drug Discovery, Research Triangle Institute, Research Triangle Park, NC (Dr Blough).
S Stevens NegusDepartment of Pharmacology and Toxicology, Virginia Commonwealth University, Richmond, VA (Drs Banks, Hutsell, Negus, and Mr Poklis); Institute for Drug and Alcohol Studies, Virginia Commonwealth University, Richmond, VA (Drs Banks and Negus); Center for Drug Discovery, Research Triangle Institute, Research Triangle Park, NC (Dr Blough).
RTI International · USVirginia Commonwealth University · US

Funding

TRAINING IN THE PHARMACOLOGY OF ABUSED DRUGST32DA007027 · NIDA · VIRGINIA COMMONWEALTH UNIVERSITY · PI William L. Dewey · 1985 to 2026
$14.7M
VCU Center for Drug Addiction ResearchP30DA033934 · NIDA · VIRGINIA COMMONWEALTH UNIVERSITY · PI JOLENE J WINDLE · 2014 to 2026
$13.8M
POTENTIAL TREATMENT MEDICATIONS FOR DRUG ABUSER01DA012970 · NIDA · RESEARCH TRIANGLE INSTITUTE · PI BLOUGH, BRUCE E · 1999 to 2013
$5.5M
Medications Development for Stimulant AbuseR01DA026946 · NIDA · VIRGINIA COMMONWEALTH UNIVERSITY · PI NEGUS, SIDNEY S · 2009 to 2019
$3.7M
NIDA NIH HHS P30 DA033934NIDA NIH HHS P30-DA033934NIDA NIH HHS R01 DA012970NIDA NIH HHS R01-DA012970NIDA NIH HHS R01 DA026946NIDA NIH HHS R01-DA026946NIDA NIH HHS T32 DA007027NIDA NIH HHS T32-DA007027
6 · The paper itself

Abstract

backgroundChronic amphetamine treatment decreases cocaine consumption in preclinical and human laboratory studies and in clinical trials. Lisdexamfetamine is an amphetamine prodrug in which L-lysine is conjugated to the terminal nitrogen of d-amphetamine. Prodrugs may be advantageous relative to their active metabolites due to slower onsets and longer durations of action; however, lisdexamfetamine treatment's efficacy in decreasing cocaine consumption is unknown.

methodsThis study compared lisdexamfetamine and d-amphetamine effects in rhesus monkeys using two behavioral procedures: (1) a cocaine discrimination procedure (training dose = 0.32mg/kg cocaine, i.m.); and (2) a cocaine-versus-food choice self-administration procedure.

resultsIn the cocaine-discrimination procedure, lisdexamfetamine (0.32-3.2mg/kg, i.m.) substituted for cocaine with lower potency, slower onset, and longer duration of action than d-amphetamine (0.032-0.32mg/kg, i.m.). Consistent with the function of lisdexamfetamine as an inactive prodrug for amphetamine, the time course of lisdexamfetamine effects was related to d-amphetamine plasma levels by a counter-clockwise hysteresis loop. In the choice procedure, cocaine (0-0.1mg/kg/injection, i.v.) and food (1g banana-flavored pellets) were concurrently available, and cocaine maintained a dose-dependent increase in cocaine choice under baseline conditions. Treatment for 7 consecutive days with lisdexamfetamine (0.32-3.2mg/kg/day, i.m.) or d-amphetamine (0.032-0.1mg/kg/h, i.v.) produced similar dose-dependent rightward shifts in cocaine dose-effect curves and decreases in preference for 0.032mg/kg/injection cocaine.

conclusionsLisdexamfetamine has a slower onset and longer duration of action than amphetamine but retains amphetamine's efficacy to reduce the choice of cocaine in rhesus monkeys. These results support further consideration of lisdexamfetamine as an agonist-based medication candidate for cocaine addiction.

Indexed as

AnimalsChoice BehaviorCocaineCocaine-Related DisordersConditioning, OperantDextroamphetamineDiscrimination, PsychologicalDopamine Uptake InhibitorsDose-Response Relationship, DrugDrug Evaluation, PreclinicalFood PreferencesLisdexamfetamine DimesylateMacaca mulattaMaleSelf AdministrationTime FactorsCocaineDextroamphetamineDopamine Uptake InhibitorsLisdexamfetamine DimesylateaddictionchoicecocainelisdexamfetamineLisdexamfetamine effects in rhesus monkeysrhesus monkey

Identifiers

PMID25618405
PMCPMC4458439
OpenAlexW2011448740

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.